Neovasc Inc. (TSE:NVC) – Analysts at Leerink Swann cut their FY2020 EPS estimates for Neovasc in a note issued to investors on Thursday. Leerink Swann analyst D. Antalffy now anticipates that the company will earn $0.34 per share for the year, down from their prior estimate of $0.40.
Neovasc (TSE NVC) traded up 2.30% on Monday, reaching $1.78. The company had a trading volume of 46,869 shares. The company’s 50 day moving average is $1.80 and its 200-day moving average is $1.40. Neovasc has a one year low of $0.50 and a one year high of $6.07.
Neovasc Company Profile
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
What are top analysts saying about Neovasc Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neovasc Inc. and related companies.